Martin Gartland, PhD, discusses early data on the investigational therapy, VH184, including the potential for long-acting treatment and looking to address emerging drug resistance challenges.
Martin Gartland, PhD
Advertisement
Gartland, PhD, is vice president and medicine development leader at ViiV Healthcare.
Articles by Martin Gartland, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Galidesivir Cleared for Compassionate Use in Uganda’s Ebola Outbreak
2
SNAP Trial Favors Penicillin over "Antistaphylococcal" Penicillins for Susceptible Staph Bacteremia
3
Important Clinical Practice Takeaways From the DOTs and PeterPen Trials
4
SNAP Global Trial Supports Cefazolin for MSSA Bacteremia
5